Nathan Connell Reflects on the Impact of COCs on VWD Patients Compared to Healthy People
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
”Navigating a bleeding disorder like von Willebrand Disease (VWD) can be challenging, especially when heavy menstrual bleeding is a major symptom.
Many patients use combination oral contraceptives (COCs) to manage this, but a key question has always been: “Does this affect my diagnosis?”
A recent scoping review and meta-analysis of 27 studies in Haemophilia Journal from Eve Justason, Anna Ishchuk, Benjamin P. Ott, Sophie Gibson, and Paula D. James sought to answer just that.
The researchers found that COC use did not significantly change von Willebrand factor (VWF) or factor VIII (FVIII) levels.
The meta-analysis of VWF% and FVIII% revealed no statistically significant difference between participants with and without COC use (VWF% Estimate: 2.62, p=0.4033; FVIII% Estimate: 2.99, p=0.4552).
These are important data for anyone who is faced with diagnosing VWD.
It provides crucial clarity by validating that COCs do not appear to interfere with the accurate diagnosis of VWD.
This is a vital piece of the puzzle for improving diagnostic certainty and ensuring appropriate management for individuals with bleeding disorders.”
Read the full article in Haemophilia Journal.
Article: Determining the Impact of Combination Oral Contraceptives on Von Willebrand Factor and Factor VIII in Healthy Patients and Patients With Von Willebrand Disease: A Scoping Review and Meta-Analysis
Authors: Eve Justason, Anna M. Ishchuk, Benjamin P. Ott, M. E. Sophie Gibson, Paula D. James
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Sep 18, 2025, 06:50Fetal Hereditary TTP Featured in NEJM – Senior Author Nishant Rajendra Tiwari
-
Sep 17, 2025, 10:54Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
-
Sep 17, 2025, 08:16Superficial Vein Thrombosis Management: John Fanikos Shares Latest Review
-
Sep 17, 2025, 07:00Maha Othman - ''BIC 2025 is Without a Doubt a Remarkable Scientific Event — and I’m Excited for What Lies Ahead!''
-
Sep 16, 2025, 11:17Glenn Pierce: WHO Issues a Biannual Essential Medicines List
-
Sep 18, 2025, 07:00Rishabh Singh on NEJM Letter: FVIII Aurora Mutation Shows Increased Activity and Reduced APC Response
-
Sep 18, 2025, 02:25Flora Peyvandi Highlights 'Inflammatory Memory of Stem Cells' – New Insights for Hematologic Diseases
-
Sep 17, 2025, 16:32Endovascular Today: Dr. Eric Secemsky Analyzes Impact of Paclitaxel Pause on Peripheral Artery Disease Care
-
Sep 17, 2025, 16:28Haemnet Showcases Research on Severe Haemophilia A Patients Adapting to Emicizumab Therapy
-
Sep 17, 2025, 16:19Todd Villines: Coronary Artery Disease - A BIG Movement to Change
-
Sep 16, 2025, 14:59A New Era in Antiplatelet Therapy for CABG?
-
Sep 16, 2025, 07:44Artificial Blood Breakthrough in Japan: Long Shelf Life, No Type Matching, and a Purple Future
-
Sep 16, 2025, 02:44Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 18, 2025, 06:34'A New Era in Mechanical Thrombectomy?' – Sripal Bangalore Highlights SYMPHONY-PE IDE Study
-
Sep 17, 2025, 10:49Living with Glanzmann Thrombasthenia․ Eliza VanZweden’s Story of Resilience and Advocacy
-
Sep 17, 2025, 10:22Abdul Mannan: Turning Medical Podcasts into Active Learning with Structured Tools
-
Sep 17, 2025, 09:43Global Blood Supply Under Threat: David McIntosh Calls for Action to Support Transfusion Services
-
Sep 17, 2025, 09:08Coronary Arteries, Pericardial Cavity, and the Hidden Danger of Cardiac Tamponade During PCI-By Ahmed Ata